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Abstract: Dry age-related macular degeneration (AMD), also called geographic atrophy, 
is characterized by the atrophy of outer retinal layers and retinal pigment epithelium (RPE) 
cells. Dry AMD accounts for 80% of all intermediate and advanced forms of the disease. 
Although vision loss is mainly due to the neovascular form (75%), dry AMD remains a 
challenge for ophthalmologists because of the lack of effective therapies. Actual manage-
ment consists of lifestyle modification, vitamin supplements, and supportive measures in 
the advanced stages. The Age-Related Eye Disease Study demonstrated a statistically sig-
nificant protective effect of dietary supplementation of antioxidants (vitamin C, vitamin E, 
beta-carotene, zinc, and copper) on dry AMD progression rate. It was also stated that the 
consumption of omega-3 polyunsaturated fatty acids, such as docosahexaenoic acid and 
eicosapentaenoic acid, has protective effects. Other antioxidants, vitamins, and minerals 
(such as crocetin, curcumin, and vitamins B9, B12, and B6) are under evaluation, but the 
results are still uncertain. New strategies aim to 1) reduce or block drusen formation, 2) 
reduce or eliminate inflammation, 3) lower the accumulation of toxic by-products from the 
visual cycle, 4) reduce or eliminate retinal oxidative stress, 5) improve choroidal perfusion, 
6) replace/repair or regenerate lost RPE cells and photoreceptors with stem cell therapy, 
and 7) develop a target gene therapy.
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Introduction
Age-related macular degeneration (AMD) is a complex and widespread disease that 
represents a public health problem and a significant challenge for current economic 
models. The general consensus states that as the population grows and ages, the 
incidence of the disease will increase as well. Major breakthroughs have been made 
in the past decades in treating the wet form of AMD and near-term prognosis has 
improved significantly. Despite every effort, AMD therapy is still not able to prevent 
or cure this pathology. While preventive genetic screening and counseling are under 
supervision and may be important parts of preventive medicine, there is a growing 
need for new treatment options for AMD. In this review, we focus on dry AMD. 
It accounts for 80% of all intermediate and advanced forms of the disease. Although 
vision loss is mainly due to the wet form (75%), dry AMD remains a challenge for 
ophthalmologists because of the lack of effective therapies. Actual management of 
this form is only based on lifestyle modification, vitamin supplements, and supportive 
measures in the advanced stages.
This article reviews the epidemiological and pathological features, as well as cur-
rent and potential treatment approaches, of dry AMD.
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Epidemiology, etiology, natural 
history, and prognosis of dry AMD
Epidemiology
AMD is a disorder of the central part of the retina – macula – 
causing progressive impairment of central vision.
It is considered the leading cause of visual disability and 
blindness in people over 60 years of age in many Western 
countries, with severe vision loss occurring in approximately 
10%–15% of people with AMD. Allikmets et al1 found that 
AMD affects at least eleven million people in the USA and 
1.2 million people are legally blind as a result of the disease.
Dry AMD, also called geographic atrophy (GA), is 
characterized by outer retinal and retinal pigment epithelium 
(RPE) atrophy and accounts for 80% of all intermediate and 
advanced forms of the disease. Wet AMD – neovascular, 
exudative – is caused by choroidal neovascularization growth 
under the RPE and the retina, exudative hemorrhages and 
disciform scarring. Vision loss is mainly due to neovascu-
lar AMD (75%) rather than dry AMD (25%).2 The 5-year 
incidence of advanced AMD, as reported in one of the most 
important population-based studies – the Beaver Dam Eye 
Study – appears to be 0.9%, with neovascular AMD affecting 
0.6% of eyes among the general population and dry AMD 
developing in 0.3% of cases. Age seems to be the most 
important risk factor. The prevalence of AMD is approxi-
mately 0% at 50 years, then rises to 2% at 70 years and to 
6% by the age of 80 years, as stated by Zarbin.3 This part of 
the population is expected to grow within the next decade, 
and by 2020, nearly 50% of the population in the Western 
world will have AMD.4 Early AMD is usually associated 
with vision impairment, while late-AMD patients have more 
severe or even complete vision loss.
Etiology
Apart from age, MD is a complex multifactorial disease, 
wherein individual genetic susceptibilities – together with 
environmental factors and metabolic conditions – contribute 
to the clinical manifestations of the disorder. Smoking is 
the second most significant risk factor, especially for dry 
AMD (odds ratio [OR]: 4.5), suggesting a chronic reduc-
tion in oxygen supply due to a reduction of blood and tissue 
oxygen partial pressure (pO2), along with a tendency to 
ischemic injury.5
Clemons et al6 reported in the Age-Related Eye Disease 
Study (AREDS, 2005) that the prevalence of AMD is higher 
in white than in nonwhite people. Contrasting results regard-
ing other risk factors, such as sex or chronic light exposure, 
have been reported over the years.7–9
The hallmark of AMD is the presence of drusen. Drusen 
are classified as basal linear deposits (BlinD), basal laminar 
deposits (BlamD), and drusen.10–12 They consist of debris 
accumulated between RPE cells and Bruch’s membrane. 
BlamD and BlinD are very small and can be observed only 
histologically, by light or electron microscopy. Drusen, 
instead, are easily seen during a fundus oculi slit-lamp 
examination. They are bigger, round shaped, and yellowish. 
Two different drusen types can be observed. Hard drusen, 
smaller and with clear margins, may be present both in nor-
mal aging eyes and in AMD eyes.13 In some diseases, such 
as MDs, long-standing retinal detachment, choroidal nevi, 
or others, we can find some punctuate deposits that look 
like hard drusen. Histologically, they share some but not all 
components with drusen, probably accounting for a different 
etiopathogenesis.14 Although hard drusen can be found in 
95% of the aged population, they are more common in dry 
AMD, and when associated with retinal pigment alterations 
and/or soft drusen, the risk of progression is increased.2,5,15 
Soft drusen are bigger and with indistinct margins. They 
represent a major risk factor for AMD evolution to advanced 
stages, both neovascularization and GA.16 Most of drusen 
components are released by the RPE, the neural retina, the 
choroidal cells, and extraocular sources and all contribute 
to drusen formation.17–19 The origin of drusen is not fully 
understood, though several hypotheses coexist: the ques-
tion whether they are derived from the RPE or the choroidal 
vasculature still remains unanswered. Currently, evidence 
suggests that both structures contribute to its formation.5 RPE 
dysfunction and failure of phagocytosis result in debris accu-
mulation in the extracellular space. Alterations of choroidal 
permeability lead to the same accumulation.
Epidemiological studies suggest that oxidative stress 
is associated with both the incidence and the progression 
of AMD. In fact, even though oxidative stress is one of 
the physiological changes that presents with aging, it is an 
important cause of retinal damage progression in AMD, as 
proved in the AREDS, wherein antioxidant supplementations 
were able to prevent the progression of intermediate and late 
forms of the disease.5,6
Growing evidence suggests that AMD is downstream 
of a chronic inflammatory condition wherein activation 
of the immune system plays an important role. Metabolic 
products accumulate in the extracellular space between 
Bruch’s membrane and the RPE, activating the complement 
system with a significant increase in oxidative stress, similar 
to what happens in atherosclerosis or Alzheimer’s disease 
(AD). A variety of drusen components have been recognized: 
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proteins (major histocompatibility complex-II, β-amyloid, 
apolipoproteins A and E, cytokines, and fibronectin), phos-
pholipids, lipofuscin, advanced glycation end products, and 
acute-phase proteins that can activate the complement system 
in response to infections (Chlamydia pneumoniae).20,21 An 
important regulatory complement protein is complement 
factor H (CFH), a major inhibitor of the alternative comple-
ment cascade that prevents the complement components from 
excessive activation to different stimuli; CFH is synthesized 
by RPE cells.
Recent studies have demonstrated that a certain poly-
morphism of a gene in chromosome 1 that encodes CFH 
would increase the risk of AMD. This higher susceptibility 
is observed when a tyrosine amino acid 402 is substituted 
by a histidine and such a variant may explain up to 50% of 
AMD cases.15,20
Genetic variants of CFH are associated with a higher 
risk of AMD. A heterozygous mutation confers a two- to 
four-fold increased risk, whereas a homozygous mutation 
augments it to five- to seven-fold.
Epidemiological studies suggest that oxidative stress is 
able to increase both the incidence and the progression of 
AMD.
Furthermore, antioxidant supplementations were able 
to prevent the progression of intermediate and late forms 
of the disease.5,6
Natural history and prognosis
Nonexudative AMD has a better prognosis compared to wet 
AMD.22 GA tends to enlarge over time at variable rates to 
cover the entire macula, typically sparing the foveal zone 
until the late stages of the disease. The effect of GA on 
visual acuity (VA) deterioration is crucial; in fact, atrophy 
spreads at a median rate of 1.72 mm2 per year and it usually 
takes a number of years from the onset of GA to cause 
consistent visual loss.23,24 The rate of significant visual loss 
(three or more lines) is reported to be 8% per year.25 The 
histopathological analysis of dry AMD shows an alteration 
of the blood–retinal barrier. RPE cellular components show 
postmitotic damage, with consequent epithelium involu-
tion, photoreceptor loss, atrophy of outer retinal layers, 
and choroidal degeneration. RPE reacts to this loss of cells 
with pigment clumps around the area of atrophy, typically 
hyperfluorescent.22,26 Areas of increased autofluorescence 
are constituted of lipofuscin accumulation within the dam-
aged RPE.23 Their tendency to enlarge is now considered a 
prognostic factor for the progression of atrophy and absolute 
scotoma, therefore for visual loss.
Summary of current management 
strategies
Dry AMD management consists of lifestyle modification, 
vitamin supplements, and supportive measures in advanced 
stages.
Together with the reduction of body mass index and 
avoidance of heavy alcohol consumption, lifestyle modifica-
tions such as physical activity and quitting smoking are also 
recommended.
Smoking
With its ability to increase the oxidative stress and to depress 
the natural antioxidant system, smoking is significantly asso-
ciated with increased risk of development and progression of 
AMD (Early AMD, GA, and choroidal neovascularization).
It is known that smoking may slow down choroidal blood 
flow, promoting ischemia, hypoxia, and microinfarctions, result-
ing in a reduction of macular pigments and damage of the RPE.
According to a recent review, there is a dose–effect rela-
tionship between the number of years smoking/pack-years 
smoked and the risk of developing AMD.27
Physical activity
Even though there is no evidence about interactions between 
active lifestyle and the development of the disease, it is 
known that physical activity reduces both systemic inflam-
mation and endothelial dysfunction, both of which contribute 
to AMD pathogenesis.
Alcohol consumption
Although alcohol consumption could hypothetically be both 
harmful and protective for AMD Chong et al28 in a system-
atic review and meta-analysis found an increased risk for 
early AMD in heavy alcohol consumers (OR: 1.47; 95% 
confidence interval, 1.10–1.95). The association between 
late AMD and heavy alcohol consumption varied in the four 
analyzed studies, nonetheless in three of them the correlation 
was positive. The review could not precisely access the role 
of moderate alcohol consumption on early AMD.
Obesity
The Atherosclerosis Risk in Communities Study states that 
middle-aged people with a waist–hip ratio reduction over 
time were less likely to develop AMD, particularly those 
who were initially obese.29
Diet
The 10-year incidence of AMD in The Blue Mountain 
Eye Study and the Alienor Study confirmed that there is a 
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decreased risk for AMD in patients with high intake of long-
chain omega-3 polyunsaturated fatty acids.30
Dietary supplementation has been thoroughly investi-
gated by AREDS 1 and 2 and their results will be discussed 
in the next section.
Supportive measures
Low-vision rehabilitation is the best option when medical 
or surgical treatments are unsuccessful or contraindicated. 
Typical supportive measures include assessment of residual 
functions and functional vision, identification of preferred 
retinal loci and training in their active use, prescription and 
training in the use of low-vision aids, training and educational 
programs (orientation and mobility), and assistance with 
daily activities. A systematic review underlines the fact that 
in the absence of adequate clinical trials, it is impossible 
to form stronger conclusions regarding the most effective 
low-vision interventions for individuals with AMD.31 Some 
authors state that augmented low-vision rehabilitation pro-
grams are as effective in improving activities of daily living 
or quality of life as conventional in-clinic rehabilitation 
programs.32
Review of recent developments 
in dry AMD management
Regarding dietary supplementation, the two most important 
studies are the AREDS and the AREDS 2.33,34
In the AREDS, the following different antioxidants were 
administered: vitamin C (500 mg), vitamin E (400 interna-
tional units [IU]), beta-carotene (15 mg), zinc (80 mg), and 
copper (2 mg).
Antioxidants
As the retina is particularly susceptible to oxidative stress, 
the use of antioxidants may prevent its damage due to 
reactive oxygen species. The latter play a role in modulating 
the nuclear factor erythroid 2-related factor 2, involved in 
the regulation of expression of genes encoding antioxidant 
proteins.35
Zinc
The development of the disease seems to be influenced by 
a dysregulation and excessive activation of the complement 
cascade, leading to accumulation of sub-RPE deposits.
Klevering36 in a recent study highlighted that daily zinc 
supplements for 3 months during AMD could lower the 
excessive systemic complement activation. However, the 
benefit of zinc is still debated and a recent meta-analysis 
confirmed that available data about its role in prevention of 
AMD are inconclusive.37
Copper
This essential element was evaluated in the AREDS, but its 
role as a protective agent remains uncertain. In order to avoid 
a copper deficiency anemia due to zinc intake, this essential 
trace element, a scavenger of free radicals, has been added 
in the AREDS. Anyway, its role in AMD protection is still 
uncertain.38
In AREDS, there was a statistically significant reduc-
tion in odds for the development of advanced AMD with 
the use of antioxidants (vitamin C, vitamin E, and beta-
carotene,) plus zinc and copper. In particular, this reduction 
was more significant in eyes with extensive intermediate 
drusen, GA not involving the center of the macula, or at 
least one large drusen (AREDS category 3) and in people 
with advanced AMD or VA less than 20/32 in one eye 
(AREDS category 4).33
A systematic review and meta-analysis by Chong et al39 
suggested that vitamin A, vitamin C, vitamin E, zinc, lutein, 
zeaxanthin, alpha- and beta-carotene, beta-cryptoxanthin, and 
lycopene had little or no effect in the primary prevention of 
early AMD. In a systematic review in 2008, the same authors 
reported that the consumption of omega-3 polyunsaturated 
fatty acids, such as docosahexaenoic acid (DHA) and eicosa-
pentaenoic acid (EPA), show protective effects against the 
progression of AMD.40
The randomized controlled trial AREDS 2, published 
in 2013, investigated the risk of progression from early to 
advanced AMD.
Three different formulations were evaluated: one with-
out beta-carotene (due to an increased risk of lung cancer 
in smokers and former smokers), another one with a lower 
dose of zinc (25 mg), and the third one with both these con-
ditions. Lower dose of zinc was chosen because of the risk 
of gastrointestinal and genitourinary diseases that zinc itself 
can induce and because its absorption has been found to be 
the same even with lower doses.34 The results showed that 
the addition of lutein + zeaxanthin, DHA + EPA, or both 
to the AREDS formulation had no positive effect on the 
progression to advanced AMD.
The difference between low-dose versus high-dose zinc 
was not statistically significant, but lutein + zeaxanthin may 
be a useful carotenoid substitute in the AREDS formulation 
in smokers and former smokers (Table 1).34
Recent studies discuss the possible positive effects of 
other antioxidants, vitamins, and minerals (Table 2).
Clinical Ophthalmology 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
567
Recent developments in the management of dry AMD
T
ab
le
 1
 C
ha
ra
ct
er
is
tic
s 
of
 A
R
ED
S 
1 
an
d 
A
R
ED
S 
23
3,
34
A
R
E
D
S 
1
A
R
E
D
S 
2
Pe
ri
od
19
92
–2
00
1
20
06
–2
01
2
D
es
ig
n
M
ul
tic
en
te
r,
 p
ha
se
 3
, r
an
do
m
iz
ed
 c
on
tr
ol
le
d 
cl
in
ic
al
 t
ri
al
M
ul
tic
en
te
r,
 p
ha
se
 3
, r
an
do
m
iz
ed
 c
on
tr
ol
le
d 
cl
in
ic
al
 t
ri
al
Pa
rt
ic
ip
an
ts
3,
60
9 
el
ig
ib
le
*
4,
18
6 
el
ig
ib
le
A
ve
ra
ge
 fo
llo
w
-u
p
6.
3 
ye
ar
s
5 
ye
ar
s
En
ro
llm
en
t 
cr
ite
ri
a
– 
 Ex
te
ns
iv
e 
sm
al
l d
ru
se
n,
 in
te
rm
ed
ia
te
 d
ru
se
n,
 la
rg
e 
dr
us
en
, n
on
ce
nt
ra
l G
A
, o
r 
pi
gm
en
t 
ab
no
rm
al
iti
es
 
in
 o
ne
 o
r 
bo
th
 e
ye
s
– 
Bi
la
te
ra
l l
ar
ge
 d
ru
se
n 
or
 n
on
fo
ve
al
 G
A
– 
 A
dv
an
ce
d 
A
M
D
 o
r 
vi
si
on
 lo
ss
 d
ue
 t
o 
A
M
D
  
in
 o
ne
 e
ye
– 
 La
rg
e 
dr
us
en
 o
r 
no
nf
ov
ea
l G
A
 in
 o
ne
 e
ye
 
an
d 
ad
va
nc
ed
 A
M
D
 in
 t
he
 fe
llo
w
 e
ye
– 
 A
t 
le
as
t 
on
e 
ey
e 
ha
d 
be
st
-c
or
re
ct
ed
 v
is
ua
l a
cu
ity
  
of
 2
0/
32
 o
r 
be
tt
er
R
an
do
m
iz
at
io
n
Su
pp
le
m
en
ta
tio
n
Pr
im
ar
y
Se
co
nd
ar
y
1.
  A
nt
io
xi
da
nt
s:
 v
ita
m
in
 C
, 5
00
 m
g;
 v
ita
m
in
 E
, 4
00
 IU
; 
be
ta
-c
ar
ot
en
e,
 1
5 
m
g
1.
 L
ut
ei
n,
 1
0 
m
g;
 z
ea
xa
nt
hi
n,
 2
 m
g
1.
 A
R
ED
S 
1 
fo
rm
ul
at
io
n 
un
ch
an
ge
d
2.
 Z
in
c,
 8
0 
m
g;
 a
nd
 c
op
pe
r,
 2
 m
g;
2.
 ω
-3
 L
C
PU
FA
s:
 D
H
A
, 3
50
 m
g;
 E
PA
, 6
50
 m
g
2.
 A
R
ED
S 
1 
fo
rm
ul
at
io
n 
w
ith
 z
in
c,
 2
5 
m
g
3.
 A
nt
io
xi
da
nt
s 
pl
us
 z
in
c
3.
 C
om
bi
na
tio
n 
of
 1
 a
nd
 2
3.
  A
R
ED
S 
1 
fo
rm
ul
at
io
n 
w
ith
ou
t 
be
ta
-c
ar
ot
en
e
4.
 P
la
ce
bo
4.
 P
la
ce
bo
4.
 C
om
bi
na
tio
n 
of
 2
 a
nd
 3
Pr
im
ar
y 
ou
tc
om
es
1.
  P
ho
to
gr
ap
hi
c 
as
se
ss
m
en
t 
of
 p
ro
gr
es
si
on
 t
o 
or
 
tr
ea
tm
en
t 
fo
r 
ad
va
nc
ed
 A
M
D
1.
 P
ho
to
gr
ap
hi
c 
as
se
ss
m
en
t 
of
 p
ro
gr
es
si
on
 t
o 
ad
va
nc
ed
 A
M
D
2.
  A
t 
le
as
t 
m
od
er
at
e 
vi
su
al
 a
cu
ity
 lo
ss
 fr
om
 b
as
el
in
e 
(
15
 le
tt
er
s)
Se
co
nd
ar
y 
ou
tc
om
es
1.
 V
is
ua
l a
cu
ity
 lo
ss
 a
tt
ri
bu
ta
bl
e 
to
 A
M
D
1.
  E
ffe
ct
 o
f t
he
 p
ri
m
ar
y 
ra
nd
om
iz
at
io
n 
su
pp
le
m
en
ts
 o
n 
pr
og
re
ss
io
n 
to
 m
od
er
at
e 
vi
si
on
 lo
ss
2.
 M
ar
ke
d 
vi
su
al
 a
cu
ity
 lo
ss
2.
 E
ffe
ct
 o
f t
he
 p
ri
m
ar
y 
ra
nd
om
iz
at
io
n 
su
pp
le
m
en
ts
 o
n 
pr
og
re
ss
io
n 
of
 le
ns
 o
pa
ci
ty
3.
  V
is
ua
l a
cu
ity
 lo
ss
 in
 e
ye
s 
w
ith
 a
dv
an
ce
d 
A
M
D
 a
t 
ba
se
lin
e
3.
 E
ffe
ct
 o
f t
he
 p
ri
m
ar
y 
ra
nd
om
iz
at
io
n 
su
pp
le
m
en
ts
 o
n 
vi
si
on
4.
 D
ev
el
op
m
en
t 
of
 n
eo
va
sc
ul
ar
 A
M
D
4.
  E
ffe
ct
 o
f t
he
 v
ar
ia
tio
ns
 o
f t
he
 A
R
ED
S 
1 
su
pp
le
m
en
ts
 o
n 
pr
og
re
ss
io
n 
to
 a
dv
an
ce
d 
A
M
D
5.
  D
ev
el
op
m
en
t 
of
 G
A
 in
 t
he
 c
en
te
r 
of
 t
he
 m
ac
ul
a*
*
5.
  E
ffe
ct
 o
f t
he
 v
ar
ia
tio
ns
 o
f t
he
 A
R
ED
S 
su
pp
le
m
en
ts
 o
n 
pr
og
re
ss
io
n 
to
 m
od
er
at
e 
vi
si
on
 lo
ss
 
6.
  P
ro
gr
es
si
on
 o
f A
M
D
 in
 c
at
eg
or
y 
2 
pa
rt
ic
ip
an
ts
R
es
ul
ts
A
M
D
 p
ro
gr
es
si
on
A
M
D
 p
ro
gr
es
si
on
 in
 p
ri
m
ar
y 
ra
nd
om
iz
at
io
n
G
ro
up
s
R
is
k 
re
du
ct
io
n 
in
 A
M
D
  
ca
te
go
ri
es
 2
, 3
 a
nd
 4
R
is
k 
re
du
ct
io
n 
in
 A
M
D
  
ca
te
go
ri
es
 3
 a
nd
 4
G
ro
up
s
R
is
k 
re
du
ct
io
n
A
nt
io
xi
da
nt
s 
vs
 n
o 
an
tio
xi
da
nt
s
N
on
si
gn
ifi
ca
nt
N
on
si
gn
ifi
ca
nt
Lu
te
in
 +
 z
ea
xa
nt
hi
n 
vs
 p
la
ce
bo
N
on
si
gn
ifi
ca
nt
 
Z
in
c 
vs
 n
o 
zi
nc
Su
gg
es
tiv
e
Si
gn
ifi
ca
nt
D
H
A
 +
 E
PA
 v
s 
pl
ac
eb
o
N
on
si
gn
ifi
ca
nt
A
nt
io
xi
da
nt
s 
vs
 p
la
ce
bo
N
on
si
gn
ifi
ca
nt
N
on
si
gn
ifi
ca
nt
Lu
te
in
 +
 z
ea
xa
nt
hi
n 
+ 
D
H
A
 +
 
EP
A
 v
s 
pl
ac
eb
o
N
on
si
gn
ifi
ca
nt
Z
in
c 
vs
 p
la
ce
bo
Su
gg
es
tiv
e
Si
gn
ifi
ca
nt
A
nt
io
xi
da
nt
s 
+ 
zi
nc
 v
s 
pl
ac
eb
o
Si
gn
ifi
ca
nt
Si
gn
ifi
ca
nt
(C
on
tin
ue
d)
Clinical Ophthalmology 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
568
Buschini et al
Crocetin
It is a natural carotenoid dicarboxylic acid, found in saffron, 
which seems to inhibit caspase activity, reduce the oxidative 
stress, and protect the retinal tissue from exposure to damag-
ing light in experimental models.41 Beyond its antioxidative 
power, evidence shows that short-term saffron supplementa-
tion improves retinal flicker sensitivity in early AMD.42
Curcumin
It can reduce lipid peroxidation and formation of reactive 
oxygen species.43 Its effect on RPE was demonstrated in in-
vitro models only. In a recent article, Chang et al44 used RPE-
like cells derived from pluripotent stem cells from patients 
with dry AMD. Pretreatment with curcumin had a cytoprotec-
tive effect against the oxidative stress of H
2
O
2
 through the 
reduction of H
2
O
2
-induced cell death and reduced reactive 
oxygen species levels. Furthermore, curcumin modulated the 
expression of many oxidative stress-regulating genes, such as 
platelet-derived growth factor, vascular endothelial growth 
factor (VEGF), heme oxygenase 1, and others.44
Vitamins B9, B12, and B6
These are currently under study in the prevention of AMD 
but their roles are still uncertain. Beyond their antioxidative 
powers, they can decrease the serum homocysteine level, 
reducing the risk of vascular diseases.
Christen et al45 in a recent randomized trial, stated 
that participants who took daily supplements of folic acid 
(vitamin B9), pyridoxine (vitamin B6), and cyanocobalamin 
(vitamin B12) had a decreased risk of AMD.
The richest sources of resveratrol (3,4,5-trihydroxystilbene) 
are grape skin and seeds, having well known antiaging, anti-
cancer, and cardioprotective properties. In in vitro models of 
RPE cells, these effects seem to be present through the inhibi-
tion of mitogen-activated protein kinase/extracellular signal-
regulated protein kinase and the VEGF expression.46,47
Key concepts of dry AMD
•	 Reducing risk factors and providing lifestyle modifica-
tions are management strategies that can prevent develop-
ment and progression of the disease.
•	 To date, antioxidant supplementation together with intake 
of some essential elements did not prove effective in 
primary prevention of AMD.
•	 In two randomized controlled trials, the use of antioxidants 
plus zinc and copper was able to reduce the risk of progres-
sion to advanced AMD (in AREDS) and the antioxidant 
carotenoid could be replaced by lutein and zeaxanthin in 
smokers and former smokers (in AREDS 2).T
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•	 New therapeutic approaches target drusen forma-
tion, inflammation, oxidative stress, accumulation of 
toxic by-products, choroidal perfusion, RPE cells, and 
photoreceptors.
•	 Future developments in genetics could clarify individual 
susceptibilities and new targeted therapies.
Future research and directions
To date, the only therapy available for early AMD and GA 
is daily intake of antioxidant formulations.
New knowledge in AMD molecular pathogenesis can 
help us to identify possible therapeutic targets to reduce/stop 
the stimuli of continuous damage or even to replace, repair, 
or regenerate the damaged cells.
New strategies are based on the following:
 1. Reduce or block drusen formation.
 2. Reduce or eliminate inflammation.
 3.  Lower the accumulation of toxic by-products from 
visual cycle.
 4. Reduce or eliminate retinal oxidative stress.
 5. Improve choroidal perfusion.
 6.  Replace, repair, or regenerate lost RPE cells and 
photoreceptors.
 7. Gene therapy.
Reduce or block drusen formation
Drusen, both hard and soft, are easily seen during a fundus 
oculi slit-lamp examination. Almost no cases of AMD exist 
without prior drusen formation, and the rate of progression 
correlates with the number and size of drusen. Moreover, GA 
progression is correlated to drusen regression.48,49 Whether 
they represent a cause or a consequence of the disease is 
still unclear. New theories postulate that drusen could be an 
adaptive process, to confine elements potentially detrimen-
tal to the retina.50 How drusen are formed is not still clear: 
probably there is a dysregulation of the pathways responsible 
for proteins and cellular debris degradation (lysosomic and 
autophagic processes), which allows their aggregation on the 
retina.51 In addition, RPE cells are physiologically exposed 
to continuous oxidative stress, so they have a rapid turnover. 
The inflammatory response, together with the immune 
system, reacts to accumulation of waste material, creating 
chronic local inflammation that represents a nucleating site 
for the deposition of extracellular elements.52
The new therapeutic approach aims to stop disease pro-
gression, selectively blocking or slowing down the accumula-
tion of the singular drusen components (Tables 3 and 4).
Several studies have shown a correlation between 
AMD drusen and AD plaques. Both contain amyloid-β	
(Aβ), in strong association with activated complement 
components.53–55 Aβ	 	 is thought to be an activator of the 
complement system and could be a potential target for new 
therapies.51 Humanized monoclonal antibodies directed 
against Aβ		have been tested in mouse models, demonstrat-
ing that systemic immunotherapy reduces the accumula-
tion of amyloid and complement components (C3) in the 
retina, improves functional response, and obtains structural 
preservation of RPE cells.56–58 Two different humanized 
monoclonal antibodies are now under evaluation in clinical 
trials: RN6G (Pfizer, New York, NY, USA) and GSK933776 
(GlaxoSmithKline, Verona, Italy).
Another drug called glatiramer acetate has been shown to be 
able to reduce AD plaques in mice.59 The same effect has been 
demonstrated on drusen in mouse models of AMD.60,61 Clinical 
trials on glatiramer acetate and dry AMD are ongoing.
Reduce or eliminate inflammation
Many complement components and inflammatory mol-
ecules are found in drusen. Several genetic studies show a 
link between complement-related proteins and AMD risk.62 
Table 2 New antioxidants in dry AMD therapy
Nutrients and elements Effect Efficacy
Crocetin Reduces apoptosis Animal models41
Increases oxygen diffusion through plasma Humans (uncertain)42
Reduces lipid peroxidation
Upregulates trophic factors
Curcumin 	Reduces lipid peroxidation and formation 
of reactive oxygen species, modulating the 
expression of many oxidative stress-regulating 
genes, such as PDGF, VEGF, HO1, and others
In vitro models43,44
Resveratrol 	Modulates cell proliferation, apopotosis, 
and angiogenesis
In vitro models46,47
Vitamins B9, B12, and B6 Decrease serum homocysteine level Humans (uncertain)45
Abbreviations: AMD, age-related macular degeneration; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; HO1, heme oxygenase 1.
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The alternative complement pathway is thought to be the 
most involved.21,63 Modulating the complement factors may 
reduce their excessive activation and the subsequent immune-
mediated damage to the RPE.
Good results have been shown in the context of intra-
vitreal administration of an antibody against complement 
factor D, called lampalizumab (FCFD4514S; Genentech Inc, 
Roche, San Francisco, CA, USA). A phase 2 study has been 
recently completed, showing good results: 20.4% reduction 
in GA progression at month 6 and month 18, with an accept-
able safety profile.64
Anti-complement component 5 (C5) antibodies are also 
under evaluation for intravitreal administration: LFG316 
(Novartis, Basel, Switzerland), ARC1905 (Ophthotech, Princ-
eton, NJ, USA), and eculizumab (Soliris®; Alexion Pharma-
ceuticals, Cheshire, CT, USA). As drusen formation triggers 
chronic local inflammation, anti-inflammatory drugs represent 
another possible therapeutic strategy. Fluocinolone acetonide 
(Iluvien™; Alimera Sciences, Alpharetta, GA, USA) is a non-
bioerodible polyamide tube containing corticosteroid with a 
broad anti-inflammatory target. An ongoing phase 2 study aims 
to evaluate intravitreal administration in GA (Fluocinolone 
Acetonide Intravitreal Inserts in Geographic Atrophy).
Some studies have also considered rapamycin, which is 
a macrolide with anti-inflammatory activity. Two studies, 
phase 1 and phase 2, have recently been completed, evalu-
ating subconjunctival (Pilot Study of the Evaluation of 
Subconjunctival Sirolimus in the Treatment of Bilateral GA 
Associated With AMD, SIRGA) or intravitreal (Sirolimus 
for Advanced Age-Related Macular Degeneration, SIRGA2) 
administration of the drug, but the results show that it does 
not prevent GA progression.65 Conversely, it seems to be 
associated with detrimental effect on VA.
Many other drusen components could be potential targets 
for dry AMD therapy, but studies are still at a preclinical 
stage.66 For example, microglia and macrophages, in order to 
modulate its recruitment to the site of injury, or mast cells, to 
prevent its degranulation.67,68 To date, our knowledge on the 
role of inflammation and immune system is fairly advanced. It 
remains still unclear if they are protectors or drivers of retinal 
degeneration. Maybe this lack of understanding can explain 
the great amount of immune therapy failure in AMD. More 
efforts are needed to better identify new therapeutic strategies 
based on specific and well-known targets.50
Lipids are also found in drusen and several studies 
demonstrate that lipids accumulate at the site of subsequent 
Table 3 Summary of current trials on dry AMD therapy based on drusen components
Type of drug Name of the drug Way of administration Reference
Anti-β-amyloid 
antibodies
RN6G Intravenous ClinicalTrials.gov NCT01577381 (suspended)
GSK933776 Intravenous ClinicalTrials.gov. NCT01342926 (ongoing)
Glatiramer acetate Weekly injection ClinicalTrials.gov. NCT00466076 (status unknown)
Subcutaneous ClinicalTrials.gov. NCT00541333 (suspended)
Anti-C5 antibodies LFG316 Intravitreal ClinicalTrials.gov. NCT01255462 (completed, no results available)
Intravitreal ClinicalTrials.gov. NCT01527500 (recruiting patients)
ARC1905 Intravitreal ClinicalTrials.gov. NCT00950638 (completed, no results available)
Eculizumab Intravenous Results found in “The COMPLETE study” (Yehoshua et al)86
Anti-factor D antibody Lampalizumab Intravitreal Results found in “The MAHALO study” (Mones)64
Anti-inflammatory agents Fluocinolone acetonide Intravitreal ClinicalTrials.gov. NCT00695318 (ongoing)
Rapamycin Intravitreal ClinicalTrials.gov. NCT01675947 (completed, no results available)
Subconjuntival Results in “The SIRGA study” (Wong et al)65
Intravitreal ClinicalTrials.gov. NCT01445548 (completed, results  
available online)
Lipids Statins Oral Cochrane review (Gehlbach et al)72
Abbreviations: AMD, age-related macular degeneration; COMPLETE, COMPLement Inhibition with Eculizumab for the Treatment of NonExudative Age-Related Macular 
Degeneration; GA, geographic atrophy; SIRGA, Sirolimus in the Treatment of Bilateral GA Associated With AMD.
Table 4 Summary of current and future targets of dry AMD therapy based on drusen components
Targets Strategy Reference
Complement components Prevention of activation/accumulation Anderson et al21
Proteins of acute phase response to inflammation Modulation/inhibition Bowes et al66
Microglia and macrophages Modulation of recruitment to the site of injury Combadiere et al67
Mast cells Prevention of degranulation Lutty et al68
Abbreviation: AMD, age-related macular degeneration.
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formation of AMD deposits. This accumulation has a detri-
mental effect on RPE because the oxidative stress over time 
results in the formation of lipid peroxidation products that 
cannot be digested by lysosomes.69 Similar to atheroscle-
rotic plaques, these accumulations may contribute to the 
adverse effects on RPE structure and function.70,71
To date, the role of lipid metabolism in AMD is poorly 
understood, but it is clear that lowering lipid accumula-
tion in Bruch’s membrane could be an efficient strategy 
to treat AMD in the first phases. In fact, some authors 
have evaluated statin efficacy in AMD. Unfortunately, the 
results are inconclusive, as reported in a recent Cochrane 
review.72
Lower the accumulation of toxic 
by-products from visual cycle
The aim is to slow down photoreceptor activity to reduce 
the accumulation of their toxic by-products, such as 
N-retinylidene-N-retinylethanolamine (A2-E) and lipofuscin, 
preventing death of RPE and photoreceptor cells. These drugs 
are still in phase 2 studies (fenretinide and ACU-4429) or 
preclinical stage (ALK-001) but represent an exciting pos-
sibility for treating AMD.
Fenretinide
Fenretinide (RT-101; ReVision Therapeutics, San Diego, 
CA, USA) decreases the blood pool of vitamin A, which 
is the base for A2-E biosynthesis. Fenretinide has shown 
antiangiogenic and anti-inflammatory properties too.73
ACU-4429
ACU-4429 (Acucela, Inc, Seattle, WA, USA), in experimen-
tal models, decreases the accumulation of A2-E, modulating 
the enzyme RPE65 that converts trans-retinol to cis-retinol 
within the RPE and slowing down the visual cycle.
ALK-001
ALK-001 (Alkeus Pharmaceuticals, Boston, MA, USA) 
is a modified vitamin A, which avoids the dimerization of 
vitamin A molecules to form A2-E and lipofuscin.49
Reduce or eliminate retinal oxidative 
stress
Neuroprotective drugs preserve macular function by prevent-
ing apoptosis of viable RPE cells and photoreceptors. Several 
drugs are under investigation, such as ciliary neurotrophic 
factor (CNTF), brimonidine tartrate, and tandospirone, 
but none of them has shown a significant efficacy at the 
moment.
CNTF
CNTF was developed as an intravitreal sustained-release 
device for retinitis pigmentosa, and it is now studied for 
treating AMD. In animal models, it was shown to inhibit 
photoreceptor cell apoptosis. In a phase 2 clinical trial 
(NT501, Renexus, Cumberland, RI, USA) in patients with 
GA, its effect in preserving VA has been demonstrated, 
but without any significant difference from the sham 
group. No benefit in terms of the progression of lesion 
was found.74
Brimonidine tartrate
This alpha-2 adrenergic receptor agonist is able to stimulate 
the production of neurotrophic factors and protect photo-
receptor cells in animal models of retinal degeneration.75 
It is now being evaluated in a phase 2 clinical trial as an 
intravitreal implant (posterior-segment drug delivery system, 
Allergan, Irvine, CA, USA).
Tandospirone
Tandospirone (AL-8309B; Alcon, Fort Worth, TX, USA) is 
a selective serotonin 1A agonist protecting the retina from 
photooxidative stress. It has been used as a topical ophthalmic 
solution in GA, in a phase 3 trial, but discontinued in 2012 
owing to its lack of efficacy.76
Improve choroidal perfusion
The choroid provides oxygen and nourishment to the outer 
retinal layers. Impairment in choroidal blood flow is one of 
the supposed pathogenetic mechanisms of AMD. Several 
drugs have been tested, but none has demonstrated efficacy: 
eg, trimetazidine, MC-1101, sildenafil, and moxaverine.
Trimetazidine
Trimetazidine is currently used to treat angina. In a recent 
study, it failed in slowing down the progression of GA.77
MC-1101
MC-1101 (MacuCLEAR, Inc, Plano, TX, USA) has anti-
inflammatory and antioxidative properties and it is supposed 
to increase choroidal blood flow. A phase 1 study highlighted 
that patients with AMD using MC-1101 had a modest increase 
in choroidal blood flow within 2 hours postdosing.
Moxaverine
Moxaverine78 is a phosphodiesterase inhibitor that increases 
choroidal mean flow velocity in the ophthalmic artery and 
in posterior ciliary arteries. Its role in dry AMD needs to be 
investigated.
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Sildenafil
Sildenafil is effective on retinal vessels,79 but no improvement 
in choroidal blood flow has been found.
Replace, repair, or regenerate lost RPE 
cells and photoreceptors
Due to its high metabolic activity, the RPE represents an 
ideal tissue for transplantation in AMD.
Several strategies, either allogeneic or autologous, have 
been tried to transplant RPE cells in degenerated areas, with-
out great success due to80 graft rejection, poor viability of 
cells, and complex attachment to the Bruch’s membrane.
New promising approaches employ embryonic stem cells 
isolated from human blastocysts. In vitro, they are pluripotent 
and so are able to differentiate in RPE cells if adequately 
stimulated. Several surgical approaches to transplant these 
cells have been used in ongoing clinical trials.81
But what if the photoreceptor cells are dead? A new fron-
tier is now represented by the simultaneous transplantation 
of photoreceptors and RPE cells.81 Rod precursors, obtained 
from both developing retina and human embryonic stem 
cells, have been used in animal models. Transplantation of 
rod precursors has shown improved vision in mice that lack 
rod function.82,83
Gene therapy
Genomic findings of the past have identified many genes 
associated with AMD, such as CFH or age-related macu-
lopathy susceptibility 2 (ARMS281). To date, genetics has 
helped us in the risk prediction of disease development/
progression, but our knowledge is still incomplete. Future 
developments could lead us to use genetic analysis to assess 
patient response to therapy, thus helping us to choose the 
most efficient treatment option.84,85
Conclusion
In general terms, therapeutic approaches to GA should be 
aimed at reducing or blocking the noxious stimuli, protect-
ing the remaining cells, and further repairing, replacing, 
or regenerating the damaged ones. Current and continuing 
advances in understanding the molecular pathogenesis of 
early AMD and GA are identifying new relevant therapeutic 
targets, coupled with the advances in detecting and measuring 
disease progression. Breakthroughs in developing therapies 
that block and/or reverse early AMD and GA are expected. 
While there are many challenges and unmet needs in under-
standing and treating early and atrophic AMD, this is an 
exciting time to be working in this area.
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